Related references
Note: Only part of the references are listed.Inhibition of ERK1/2 and Activation of LXR Synergistically Reduce Atherosclerotic Lesions in ApoE-Deficient Mice
Yuanli Chen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Inhibition of Glutathione Production Induces Macrophage CD36 Expression and Enhances Cellular-oxidized Low Density Lipoprotein (oxLDL) Uptake
Xiaoxiao Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis
Chuan Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer
V. Craig Jordan
ENDOCRINE-RELATED CANCER (2014)
Inflammatory Stress Increases Hepatic CD36 Translational Efficiency via Activation of the mTOR Signalling Pathway
Chuan Wang et al.
PLOS ONE (2014)
Tamoxifen inhibits macrophage FABP4 expression through the combined effects of the GR and PPARγ pathways
Meixiu Jiang et al.
BIOCHEMICAL JOURNAL (2013)
Activation of Liver X Receptor Induces Macrophage Interleukin-5 Expression
Yuanli Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Induction of macrophage scavenger receptor type BI expression by tamoxifen and 4-hydroxytamoxifen
Pengzhi Dong et al.
ATHEROSCLEROSIS (2011)
Molecular therapy of breast cancer: progress and future directions
Sheng-Xiang Lin et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior
Roy L. Silverstein et al.
SCIENCE SIGNALING (2009)
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
V. Craig Jordan et al.
STEROIDS (2007)
Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma - A novel marker of insulin resistance
Aase Handberg et al.
CIRCULATION (2006)
A CD36-dependent signaling cascade is necessary for macrophage foam cell formation
S. Ohidar Rahaman et al.
CELL METABOLISM (2006)
Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice
KJ Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice
VR Babaev et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and β
AC Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin
Y Suárez et al.
CARDIOVASCULAR RESEARCH (2004)
Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women
KS Stamatelopoulos et al.
AMERICAN HEART JOURNAL (2004)
Influence of tamoxifen on carotid intima-media thickness in postmenopausal women
T Simon et al.
CIRCULATION (2002)
CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism
M Febbraio et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation
E Griffin et al.
NATURE MEDICINE (2001)
Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats
M Pravenec et al.
NATURE GENETICS (2001)
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
A Chawla et al.
MOLECULAR CELL (2001)
Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice
M Febbraio et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ
JH Han et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)